Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets
SRRK - Scholar Rock Holding Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$71.30
DETAILS
HIGH:
$84.00
LOW:
$58.00
MEDIAN:
$71.00
CONSENSUS:
$71.30
UPSIDE:
71.85%
Stock News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 17,461 shares of common stock and inducement restricted stock units, covering an aggregate of 43,559 shares of its common stock. The awards are subject to all terms and conditions and other provisi.
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA). Informed by ongoing dialogue.
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened
Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) traded down 5.1% on Monday. The stock traded as low as $44.59 and last traded at $44.4380. Approximately 908,652 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 1,414,143 shares. The stock had previously closed at $46.81.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to shareholders.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting of inducement stock options to purchase an aggregate of 23,801 shares of common stock and inducement restricted stock units, covering an aggregate of 59,301 shares of its common stock. The awards are subject to all terms and conditions and other provision.
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP
Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 211.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,933 shares of the company's stock after purchasing an additional 16,245 shares
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with expansion potential into younger populations, subcutaneous formulations, and new indications like FSHD. Regulatory catalysts include planned MAA resubmission in Europe and anticipated JNDA filing in Japan by year-end 2026, leveraging a validated manufacturing facility.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock (NASDAQ:SRRK) for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older.
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with the rare genetic disorder.
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA).
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted.
US FDA approves Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness.
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety; the alternate fill-finish facility mitigates approval risk but does not eliminate it. SAPPHIRE trial data support apitegromab's add-on value in SMA, showing statistically significant motor function gains over placebo for nonambulatory patients.
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD. In addition, the Company announced that participant dosing is underway in the Phase 2 FORGE c.
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK
Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 87,893 shares of the company's stock, valued at approximately $4,834,000. Scholar Rock makes up about 1.7%
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.
BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) in the undefined quarter, according to its most recent filing with the SEC. The fund acquired 9,494,084 shares of the company's stock, valued at approximately $522,175,000. BlackRock Inc. owned approximately 7.92% of Scholar Rock at the end of
Price Targets
Scholar Rock price target raised to $77 from $76 at Truist
$77.00
(was $48.80)
Truist Financial
Scholar Rock (SRRK) PT Raised to $70 at JPMorgan
$70.00
(was $46.65)
Cantor Fitzgerald
Scholar Rock price target raised to $72 from $65 at Evercore ISI
$72.00
(was $48.25)
Evercore ISI
Scholar Rock price target raised to $70 from $64 at Wedbush
$70.00
(was $48.29)
Wedbush
Scholar Rock price target raised to $75 from $60 at Piper Sandler
$75.00
(was $51.85)
Allison Bratzel
·
Piper Sandler
Scholar Rock price target raised to $70 from $65 at H.C. Wainwright
$70.00
(was $51.85)
H.C. Wainwright
Scholar Rock downgraded to Equal Weight from Overweight at Barclays
$58.00
(was $51.85)
Barclays
Scholar Rock price target raised to $65 from $57 at Jefferies
$65.00
(was $51.85)
Amy Li
·
Jefferies
Scholar Rock price target raised to $84 from $76 at BMO Capital
$84.00
(was $55.41)
BMO Capital
Scholar Rock (SRRK) PT Raised to $76 at Truist Securities
$76.00
(was $55.41)
Srikripa Devarakonda
·
Truist Financial
Scholar Rock (SRRK) PT Raised to $72 at Raymond James
$72.00
(was $55.41)
Martin Auster
·
Raymond James
Scholar Rock price target raised to $64 from $58 at Wedbush
$64.00
(was $55.97)
Wedbush
Scholar Rock price target raised to $76 from $70 at BMO Capital
$76.00
(was $52.18)
BMO Capital
Scholar Rock price target raised to $55 from $53 at Barclays
$55.00
(was $46.45)
Barclays
Scholar Rock price target raised to $65 from $58 at H.C. Wainwright
$65.00
(was $46.45)
H.C. Wainwright
Scholar Rock initiated with a Buy at Canaccord
$62.00
(was $47.80)
Canaccord Genuity
'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler
$58.00
(was $44.85)
Allison Bratzel
·
Piper Sandler
Scholar Rock (SRRK) PT Raised to $53 at Barclays
$53.00
(was $44.31)
Etzer Darout
·
Barclays
Scholar Rock (SRRK) PT Raised to $55 at Truist Securities
$55.00
(was $44.31)
Srikripa Devarakonda
·
Truist Financial
Scholar Rock price target raised to $58 from $44 at H.C. Wainwright
$58.00
(was $44.29)
Andres Maldonado
·
H.C. Wainwright